ReviewPharmaceutics2022
Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Efficacy and safety of antidepressants for pain in older adults: A systematic review and meta-analysis.British journal of clinical pharmacology · 2024Pooled it
- A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis.Frontiers in immunology · 2024Guideline
- Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide-Medical sciences (Basel, Switzerland) · 2025Trial
- Article
- Associations ofPharmaceuticals (Basel, Switzerland) · 2026Article
- The Role of Biomarkers in Personalized Anesthesia: From Physiological Parameters to Molecular Diagnostics.Biomedicines · 2026Review
- An investigation into the underlying mechanisms of risperidone-induced antinociception through the cholinergic pathway.Pharmaceutical science advances · 2025Article
- Analyzing the impact of pharmacogenomics-guided nonsteroidal anti-inflammatory drug alerts in clinical practice.JAMIA open · 2025Article
- The Role of Pharmacogenetic Biomarkers in Pain.Biomedicines · 2025Article
- Moving Away from One-Size-Fits-All: Assessing the Use of Pharmacogenetic-Guided Medication Therapy in Pediatric Patients with Chronic Pain.Children (Basel, Switzerland) · 2025Article
- Potential role of NSAIDs loaded nano-formulations to treat inflammatory diseases.Inflammopharmacology · 2025Review
- Intravenously Administered Nonsteroidal Anti-Inflammatory Drugs in Clinical Practice: A Narrative Review.Pharmacy (Basel, Switzerland) · 2025Review
- Decellularized liver scaffolds for constructing drug-metabolically functionalBioactive materials · 2025Article
- Synergistic Epistasis and Systems Biology Approaches to Uncover a Pharmacogenomic Map Linked to Pain, Anti-Inflammatory and Immunomodulating Agents (PAIma) in a Healthy Cohort.Cellular and molecular neurobiology · 2024Article
- Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical Applications.International journal of molecular sciences · 2024Review
- Pharmacogenetic Approaches in Personalized Medicine for Postoperative Pain Management.Biomedicines · 2024Review
- Deciphering pain: molecular mechanisms and neurochemical pathways-challenges and future opportunities.Frontiers in molecular biosciences · 2024Review
- Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder.Current neuropharmacology · 2024Review
- Article
- Precision, integrative medicine for pain management in sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThis systematic review summarizes the impact of pharmacogenetics on the effect and safety of non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants when used for pain treatment.
methodsA systematic literature search was performed according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines regarding the human in vivo efficacy and safety of NSAIDs and antidepressants in pain treatment that take pharmacogenetic parameters into consideration. Studies were collected from PubMed, Scopus, and Web of Science up to the cutoff date 18 October 2021.
resultsTwenty-five articles out of the 6547 initially detected publications were identified. Relevant medication-gene interactions were noted for drug safety. Interactions important for pain management were detected for (1) ibuprofen/
conclusionsOverall, a lack of well powered human in vivo studies assessing the pharmacogenetics in pain patients treated with NSAIDs or antidepressants is noted. Studies indicate a higher risk for partly severe side effects for the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.